Genentech Given a Second Chance to Defend Itself
Submitted by Olivia Conroy on Fri, 02/25/2011 - 12:49To prove that Avastin drug is the harmless and effectual cure for breast cancer, Genentech has been provided with an additional chance. The Genetech is the manufacturer of the drug. It will be presenting its case and all the supportive research in front of the U. S. regulators.
Insulin cells are preserved by cancer drug in diabetes
Submitted by Amit Pathania on Thu, 11/26/2009 - 06:50A drug called Rituxan, used to treat cancer and rheumatoid arthritis, could help in slowing down the development of newly discovered type1 or juvenile diabetes as per researchers' report.
Safety of Asthma Drug Xolair being Investigated by FDA
Submitted by Jason Ramsey on Sat, 07/18/2009 - 02:55The U.S. Food and Drug Administration announced Thursday it is conducting a safety review of the asthma drug Xolair after receiving reports of increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke among patients who use it.
Genentech’s breast-cancer drug Herceptin reduces stomach cancer’s fatality risk
Submitted by Aaron Ross on Mon, 06/01/2009 - 07:36According to the findings of a new research disclosed at the American Society of Clinical Oncologists' annual meeting in Orlando, Florida, Roche Holding AG's blockbuster breast-cancer drug Herceptin can also be safely used for the treatment of a subtype of stomach cancers.
Roche ups its Genentech deal by 2 percent; offering $95-per-share
Submitted by Dominic Haber on Tue, 03/10/2009 - 11:59In its endeavor to take complete control of the biotech Genentech Inc, after an eight-month association, Roche Holding AG has upped its buyout deal - for the 44 percent of the company it doesn't already own - to $46.7 billion, a 2 percent increase over its earlier offer.
Roche upgrades its Genentech takeover bid to $45.7 billion
Submitted by Jason Ramsey on Sat, 03/07/2009 - 13:18In its bid to takeover the minority shareholders of Genentech Inc, the Swiss drugmaker Roche Holding AG has made its offer more tempting - with the new proposition of $45.7 billion upgrading its offer of $86.50 a share to $93 a share!
Risk of brain infections supposedly increases with use of psoriasis drug Raptiva
Submitted by Jason Ramsey on Fri, 02/20/2009 - 08:25According to a public health advisory issued by the Food and Drug Administration, there have been reports of multifocal leukoencephalopathy (PML) - an atypical brain infection - in people being treated with the psoriasis drug Raptiva.
Genentech study’s new “clue” could be a diagnostic sign of Alzheimer’s
Submitted by Jason Ramsey on Thu, 02/19/2009 - 09:12In their latest study, published in the esteemed scientific journal Nature, the researchers at Genentech of South San Francisco and the Salk Institute of La Jolla have mentioned a new "clue" that could be a diagnostic sign of Alzheimer's disease - a disparaging neurodegenerative medical condition.











